15 mg. clinical trials

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

This study is testing a new tablet, losmapimod, for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It aims to see if the drug helps improve arm function and if it's safe to use over time.